SGT 003 - Beijing Sungen Biomedical Technology
Alternative Names: SGT-003 - Beijing Sungen Biomedical TechnologyLatest Information Update: 28 Jan 2026
At a glance
- Originator Beijing Sungen Biomedical Technology
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Regulatory T-lymphocyte inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer